Orchestra BioMed Holdings, Inc.
NASDAQ Global MarketTotal Valuation
Orchestra BioMed Holdings, Inc. carries a market capitalization of 234.13M, placing it among publicly traded companies globally. Its enterprise value stands at 138.62M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 234.13M |
| Enterprise Value | 138.62M |
Share Statistics
Orchestra BioMed Holdings, Inc. currently has 58.63M shares outstanding.
| Shares Outstanding | 58.63M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 6.64, and the price-to-book ratio stands at -0.57.
| PE Ratio | N/A |
| PS Ratio | 6.64 |
| PB Ratio | -0.57 |
| P/TBV Ratio | 5.27 |
| P/FCF Ratio | -4.03 |
| P/OCF Ratio | -3.98 |
Enterprise Valuation
| EV / Sales | 4.24 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Orchestra BioMed Holdings, Inc. maintains a current ratio of 7.03, meaning it holds 7.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 7.03 |
| Quick Ratio | 6.90 |
| Debt / Equity | 38.47 |
| Debt / EBITDA | -0.29 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -68.42 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 16.47 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.86 |
Stock Price Statistics
Orchestra BioMed Holdings, Inc.'s stock has gained approximately 20.67901% over the past 52 weeks. The 50-day moving average sits at 4.15, while the 200-day moving average is 3.89.
| Beta (5Y) | N/A |
| 52-Week Price Change | 20.67901% |
| 50-Day Moving Average | 4.15 |
| 200-Day Moving Average | 3.89 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Orchestra BioMed Holdings, Inc. generated 32.72M in revenue and converted that into -54.64M in net income, yielding earnings per share of -1.07. EBITDA reached -54.63M, while operating income came in at -54.96M.
| Revenue | 32.72M |
| Gross Profit | 32.55M |
| Operating Income | -54.96M |
| Pretax Income | -54.64M |
| Net Income | -54.64M |
| EBITDA | -54.63M |
| EBIT | -54.96M |
| Earnings Per Share (EPS) | -1.07 |
Balance Sheet
Orchestra BioMed Holdings, Inc. holds 94.40M in cash and equivalents against 15.85M in total debt, resulting in a net debt position of -14.03M. Total book value stands at -383.26M, with working capital of 82.52M providing operational flexibility.
| Cash & Cash Equivalents | 94.40M |
| Total Debt | 15.85M |
| Net Debt | -14.03M |
| Equity (Book Value) | -383.26M |
| Book Value Per Share | -7.50 |
| Working Capital | 82.52M |
Cash Flow
Orchestra BioMed Holdings, Inc. produced -54.51M in operating cash flow over the past twelve months. After subtracting -561,000.00 in capital expenditures, free cash flow totaled -55.08M - equivalent to -1.08 per share.
| Operating Cash Flow | -54.51M |
| Capital Expenditures | -561,000.00 |
| Free Cash Flow | -55.08M |
| FCF Per Share | -1.08 |
Margins
Orchestra BioMed Holdings, Inc. operates with a gross margin of 99.46, reflecting its pricing power and cost economics. The operating margin of -167.96 and net profit margin of -166.96 provide insight into operational efficiency.
| Gross Margin | 99.46 |
| Operating Margin | -167.96 |
| Pretax Margin | -166.96 |
| Profit Margin | -166.96 |
| EBITDA Margin | -166.94 |
Dividends & Yields
The company's payout ratio of -0.06 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | -0.06 |
| Shareholder Yield | -43.35 |
| FCF Yield | -24.84 |
Scores
Orchestra BioMed Holdings, Inc. posts an Altman Z-Score of -3.63, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.63 |